Merck & Co. Inc. has delivered impressive first-quarter results, highlighted by $3.25 billion in sales from its COVID-19 antiviral pill Lagevrio and a 23% year-over-year increase to $4.81 billion from its cancer drug Keytruda. The company reported earnings of $2.14 per share, exceeding analyst expectations and leading to a revised annual sales forecast of $56.9 billion to $58.1 billion. This robust financial performance has driven a 10.1% rise in Merck's stock year-to-date, reflecting strong market confidence.
“Merck's oral antiviral medicine Lagevrio · generated sales of · $3.25 billion · true”
“Merck's cancer drug Keytruda · generated sales of · $4.81 billion · up 23% year over year”
“Merck · has earnings beat · Q1 earnings · attributed to its COVID treatment pill”
“Merck (MRK) · came out with quarterly earnings of · $2.14 per share · beating the Zacks Consensus Estimate of $1.81 per share”
“Merck (MRK) · compares to earnings of · $1.40 per share · a year ago”
“Merck (MRK) · posted revenues of · $15.9 billion · for the quarter ended March 2022”
“Merck (MRK) · surpassing the Zacks Consensus Estimate by · 5.99%”
“Merck · also beat · estimates for earnings · yes”
“Merck · also beat · estimates for sales · yes”
“Merck · generated sales of · Lagevrio (molnupiravir) · $3.25 billion”
“Merck · raised · earnings expectations for 2022 · yes”
“Merck · beat · estimates for earnings and sales”
